CMG Pharmaceutical Co., Ltd. (058820.KQ)
KRW 2070.0
(-1.66%)
KRW 2070.0
(-1.66%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 5.72 Billion KRW | 1.86% |
| 2022 | 2.98 Billion KRW | 79.55% |
| 2021 | 1.66 Billion KRW | -8.88% |
| 2020 | 1.82 Billion KRW | -19.14% |
| 2019 | 2.25 Billion KRW | 540.16% |
| 2018 | 352.05 Million KRW | 23.9% |
| 2017 | 284.13 Million KRW | 386.17% |
| 2016 | 58.44 Million KRW | -92.48% |
| 2015 | 776.78 Million KRW | 8.22% |
| 2014 | 717.77 Million KRW | 33.05% |
| 2013 | 539.47 Million KRW | 17.05% |
| 2012 | 460.89 Million KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 315.71 Million KRW | 186.75% |
| 2024 Q1 | 110.1 Million KRW | 110.76% |
| 2023 Q2 | 2.48 Billion KRW | 234.09% |
| 2023 FY | 3.03 Billion KRW | 1.86% |
| 2023 Q4 | -1.02 Billion KRW | -222.39% |
| 2023 Q1 | 742.75 Million KRW | 293.43% |
| 2023 Q3 | 836.35 Million KRW | -66.3% |
| 2022 Q3 | 342.61 Million KRW | 0.1% |
| 2022 FY | 2.98 Billion USD | 79.55% |
| 2022 Q4 | -383.98 Million KRW | -212.07% |
| 2022 Q2 | 342.27 Million KRW | 75.95% |
| 2022 Q1 | 194.53 Million KRW | 19.35% |
| 2021 Q1 | 167.11 Million KRW | 27.42% |
| 2021 FY | 1.66 Billion USD | -8.88% |
| 2021 Q2 | 249.79 Million KRW | 49.48% |
| 2021 Q3 | 244.33 Million KRW | -2.18% |
| 2021 Q4 | 162.99 Million KRW | -33.29% |
| 2020 Q3 | 115.08 Million KRW | 25646.53% |
| 2020 Q1 | 80.45 Million KRW | -30.85% |
| 2020 Q2 | 447 Thousand KRW | -99.44% |
| 2020 FY | 1.82 Billion USD | -19.14% |
| 2020 Q4 | 131.14 Million KRW | 13.96% |
| 2019 Q2 | 124.5 Million KRW | 6.32% |
| 2019 Q4 | 116.35 Million KRW | -4.28% |
| 2019 Q1 | 117.1 Million KRW | 84.82% |
| 2019 Q3 | 121.54 Million KRW | -2.38% |
| 2019 FY | 2.25 Billion USD | 540.16% |
| 2018 FY | 352.05 Million USD | 23.9% |
| 2018 Q4 | 63.35 Million KRW | -21.08% |
| 2018 Q3 | 80.28 Million KRW | -27.51% |
| 2018 Q2 | 110.75 Million KRW | 13.4% |
| 2018 Q1 | 97.66 Million KRW | 54.14% |
| 2017 Q1 | 76.82 Million KRW | 137.2% |
| 2017 Q2 | 106.34 Million KRW | 38.42% |
| 2017 Q3 | 67.61 Million KRW | -36.42% |
| 2017 FY | 284.13 Million USD | 386.17% |
| 2017 Q4 | 63.36 Million KRW | -6.29% |
| 2016 FY | 58.44 Million USD | -92.48% |
| 2016 Q4 | 32.38 Million KRW | 22.85% |
| 2016 Q3 | 26.36 Million KRW | -40.2% |
| 2016 Q2 | 44.08 Million KRW | 199.31% |
| 2016 Q1 | -44.38 Million KRW | -140.7% |
| 2015 Q2 | 228.8 Million KRW | 13.27% |
| 2015 Q1 | 202 Million KRW | 6.27% |
| 2015 FY | 776.78 Million USD | 8.22% |
| 2015 Q4 | 109.06 Million KRW | -53.97% |
| 2015 Q3 | 236.91 Million KRW | 3.54% |
| 2014 Q4 | 190.08 Million KRW | -9.07% |
| 2014 Q3 | 209.04 Million KRW | 15.21% |
| 2014 Q2 | 181.44 Million KRW | 32.24% |
| 2014 Q1 | 137.2 Million KRW | 4.97% |
| 2014 FY | 717.77 Million USD | 33.05% |
| 2013 Q1 | 121.38 Million KRW | 17.74% |
| 2013 FY | 539.47 Million USD | 17.05% |
| 2013 Q3 | 139.55 Million KRW | -5.59% |
| 2013 Q2 | 147.81 Million KRW | 21.78% |
| 2013 Q4 | 130.71 Million KRW | -6.34% |
| 2012 Q4 | 103.09 Million KRW | 0.0% |
| 2012 FY | 460.89 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | -19.54 Billion KRW | 129.297% |
| Celltrion Pharm, Inc. | 36.07 Billion KRW | 84.128% |
| Huons Global Co., Ltd. | 122.92 Billion KRW | 95.342% |
| DongKook Pharmaceutical Co., Ltd. | 66.87 Billion KRW | 91.439% |
| Enzychem Lifesciences Corporation | -14.35 Billion KRW | 139.88% |
| Humedix Co., Ltd. | 37.31 Billion KRW | 84.655% |
| Boditech Med Inc. | 33.44 Billion KRW | 82.881% |
| EuBiologics Co., Ltd. | 7.69 Billion KRW | 25.638% |
| FutureChem Co.,Ltd | -8.4 Billion KRW | 168.093% |
| Huons Co., Ltd. | 59.79 Billion KRW | 90.425% |
| BNC Korea Co., Ltd. | 10.81 Billion KRW | 47.08% |
| AptaBio Therapeutics Inc. | -16.37 Billion KRW | 134.966% |